Cargando…

Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?

Detalles Bibliográficos
Autores principales:	Ray-Coquard, Isabelle, Vanacker, Hélène, Saux, Olivia Le, Tredan, Olivier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553990/ https://www.ncbi.nlm.nih.gov/pubmed/33038760 http://dx.doi.org/10.1016/j.ebiom.2020.103046

Ejemplares similares

PARP inhibitors combined with radiotherapy: are we ready?
por: Sun, Chen, et al.
Publicado: (2023)

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
por: McMullen, Michelle, et al.
Publicado: (2020)

PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies
por: Miller, Rowan E, et al.
Publicado: (2022)

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
por: Kim, Hyoung, et al.
Publicado: (2020)

First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion
por: Banerjee, Susana, et al.
Publicado: (2020)

Combining PARP and CDK4/6 inhibitors in MYC driven ovarian cancer
por: Konecny, Gottfried E.
Publicado: (2019)

PARP inhibitors are not all equal
por: Dent, Paul
Publicado: (2013)

New developments in treatment of ovarian carcinoma: focus on trabectedin
por: Cassier, Philippe A, et al.
Publicado: (2010)

Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
por: Klotz, Daniel Martin, et al.
Publicado: (2020)

Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer?
por: Batista, Thales Paulo, et al.
Publicado: (2020)

KIAA1529 regulates RAD51 expression to confer PARP inhibitors resistance in ovarian cancer
por: Qiao, Yuan, et al.
Publicado: (2022)

Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms and Clues to Overcome Resistance
por: Kyo, Satoru, et al.
Publicado: (2022)

The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer
por: Gien, Lilian T., et al.
Publicado: (2010)

Genetic counselling for hypertrophic cardiomyopathy: are we ready for it?
por: Vosberg, Hans-Peter
Publicado: (2000)

Vaccination against Lyme disease: Are we ready for it?
por: Kaaijk, Patricia, et al.
Publicado: (2015)

Nuclear Medicine in India: Are We Pandemic Ready?
por: Puranik, Ameya D
Publicado: (2020)

Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer
por: Revythis, Antonios, et al.
Publicado: (2022)

Are we ready for the new fatal Coronavirus: scenario of Pakistan?
por: Ahmad, Tauseef, et al.
Publicado: (2020)

Commentary: Are we always ready for a challenging surprise?
por: Rackauskas, Mindaugas, et al.
Publicado: (2021)

Combination Treatment Strategies to Overcome PARP Inhibitor Resistance
por: Soung, Young-Hwa, et al.
Publicado: (2023)

Mechanism of PARP inhibitor resistance and potential overcoming strategies
por: Fu, Xiaoyu, et al.
Publicado: (2023)

PARP inhibitors in ovarian cancer
por: Cibula, David, et al.
Publicado: (2015)

Emerging role of artificial intelligence in medical sciences—Are we ready!
por: Garg, Rakesh, et al.
Publicado: (2021)

Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer
por: Jiang, Yifan, et al.
Publicado: (2020)

PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them
por: Kim, Dongha, et al.
Publicado: (2022)

Blockchain in surgery: are we ready for the digital revolution?
por: Carrano, Francesco Maria, et al.
Publicado: (2022)

Regenerative Medicine for Erectile Dysfunction Following Radical Prostatectomy: Are we Ready?
por: Albersen, Maarten, et al.
Publicado: (2016)

The Elimination of Cancer Health Disparities: Are We Ready to Do the Heavy Lifting?
por: Jackson, Jonathan D., et al.
Publicado: (2016)

Move from Traditional Histopathology to Digital and Computational Pathology: Are we Ready?
por: Mubarak, Muhammed
Publicado: (2022)

PARP Inhibitors in Breast and Ovarian Cancer
por: Wang, Samuel S. Y., et al.
Publicado: (2023)

PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective
por: Loizzi, Vera, et al.
Publicado: (2020)

Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma
por: Sun, Li, et al.
Publicado: (2022)

New perspectives on epigenetic modifications and PARP inhibitor resistance in HR-deficient cancers
por: Bayley, Rachel, et al.
Publicado: (2023)

Vitamin D and Type 2 Diabetes: Are We Ready for a Prevention Trial?
por: Scragg, Robert
Publicado: (2008)

Sperm DNA fragmentation testing in male infertility work-up: are we ready?
por: Borini, Andrea, et al.
Publicado: (2017)

Pulsed-field ablation—are we ready for fast and furious atrial tachycardia ablation?
por: Heeger, Christian-Hendrik, et al.
Publicado: (2023)

Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape
por: Prados-Carvajal, Rosario, et al.
Publicado: (2021)

NHS vs Modicare: The Indian Healthcare v2.0. Are we ready to build the healthier India that we envisage?
por: Nirula, Suvansh R., et al.
Publicado: (2019)

Capitalizing on ATRX loss in glioma via PARP inhibition: Comment on “Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity” by Garbarino et al.
por: Zalenski, Abigail A, et al.
Publicado: (2021)

Targeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer
por: Zhang, Xudong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bh7b1794lksv9se27ooajpn03d